Feeding stimulated by very low doses of d-amphetamine administered systemically or by microinjection into the striatum

Amphetamine Dose-Dependently Decreases and Increases Binge Intake of Fat and Sucrose Independent of Sex

OBJECTIVE

Amphetamine was formerly used as a treatment to combat obesity, but amphetamine's use as an appetite suppressant was discontinued because of its significant abuse potential. Most of the rewarding and reinforcing effects of amphetamine differ by sex, with females showing higher levels of drug intake and amphetamine-induced motivation, relapse, and locomotion, but it is unknown whether amphetamine's effects on feeding also differ by sex. Furthermore, previous research on the anorectic effects of amphetamine has been focused primarily on its effects on baseline homeostatic feeding, but it is unknown whether amphetamine also affects hedonic, reward-related feeding, which is an important factor driving the rise in obesity levels.

METHODS

This study tested whether amphetamine alters food intake in a sex-dependent manner in two reward-related feeding paradigms: a sucrose two-bottle choice test and a high-fat/high-sugar binge intake model.

RESULTS

Amphetamine altered food intake equally in males and females in both paradigms, with higher doses significantly inhibiting feeding and low doses of amphetamine increasing feeding at later time points.

CONCLUSIONS

Amphetamine's effects on feeding and drug reward may be mediated by distinct mechanisms, which could allow for the development of new approaches to combat obesity with limited abuse and addiction-related side effects.

Dissociable effects of dopamine D1 and D2 receptors on compulsive ingestion and pivoting movements elicited by disinhibiting the ventral pallidum

Previous studies have shown that infusion of a GABAA receptor antagonist, such as bicuculline (bic), into the ventral (pallidum VP) of rats elicits vigorous ingestion in sated subjects and abnormal pivoting movements. Here, we assessed if the ingestive effects generalize to the lateral preoptic area (LPO) and tested both effects for modulation by dopamine receptor signaling. Groups of rats received injections of the dopamine D2 receptor antagonist, haloperidol (hal), the D1 antagonist, SCH-23390 (SCH), or vehicle (veh) followed by infusions of bic or veh into the VP or LPO. Ingestion effects were not observed following LPO bic infusions. Compulsive ingestion associated with VP activation was attenuated by hal, but not SCH. VP bic-elicited pivoting was attenuated by neither hal, nor SCH.

The Functional and Neurobiological Properties of Bad Taste

The gustatory system serves as a critical line of defense against ingesting harmful substances. Technological advances have fostered the characterization of peripheral receptors and have created opportunities for more selective manipulations of the nervous system, yet the neurobiological mechanisms underlying taste-based avoidance and aversion remain poorly understood. One conceptual obstacle stems from a lack of recognition that taste signals subserve several behavioral and physiological functions which likely engage partially segregated neural circuits. Moreover, although the gustatory system evolved to respond expediently to broad classes of biologically relevant chemicals, innate repertoires are often not in register with the actual consequences of a food. The mammalian brain exhibits tremendous flexibility; responses to taste can be modified in a specific manner according to bodily needs and the learned consequences of ingestion. Therefore, experimental strategies that distinguish between the functional properties of various taste-guided behaviors and link them to specific neural circuits need to be applied. Given the close relationship between the gustatory and visceroceptive systems, a full reckoning of the neural architecture of bad taste requires an understanding of how these respective sensory signals are integrated in the brain.

Animal models to explore the effects of CNS drugs on food intake and energy expenditure

Obesity has reached epidemic proportions globally with an increasing incidence not just in Western cultures but also Mexico, Brazil, China and parts of Africa. In terms of pharmacological intervention, the track record of drug treatments for obesity is poor, especially in the case of centrally acting medicines, and there remains an unmet need for the development of safer compounds delivering superior efficacy. Animal models are of importance not only in detecting changes in food intake, energy expenditure and body weight but also providing confidence that these changes are behaviourally specific and not a result of drug-induced side effects. We review animal models of feeding behaviour that are used to aid our understanding of the control of body weight and energy regulation with special reference to CNS-acting drugs. The use of such models in the discovery of new drugs for the treatment of obesity is given particular emphasis. This article is part of a Special Issue entitled 'Central Control of Food Intake'.

Enhanced food intake after stimulation of hypothalamic P2Y1 receptors in rats: modulation of feeding behaviour by extracellular nucleotides

The present study was aimed to clarify the role of purinergic signalling in the regulation of ingestion behaviour. The ATP/ADP analogues 2-methylthioATP (2-MeSATP) and adenosine 5'-O-(2-thiodiphosphate) (ADPbetaS) increased the food intake after intracerebroventricular infusion in 18-h food-deprived rats. This effect was abolished by pretreatment with the non-selective P2X/P2Y receptor antagonist pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) or the selective P2Y1 receptor antagonist MRS 2179, respectively. The stimulation of food intake mediated by ADPbetaS was also blocked by pretreatment with the nitric oxide synthase (NOS) inhibitor Nw-nitro-L-arginine methylester (L-NAME), as well as with the inhibitor of the soluble guanylyl cyclase 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), suggesting that the orexigenic effect seems to be closely related with the ensuing formation of nitric oxide. The immunohistochemical staining indicating a co-localization of P2Y1 receptor- and nNOS-immunoreactivities in a population of neurons in the ventromedial hypothalamic nucleus (VMH) agrees with this assumption. Further experiments with the direct local application of these compounds into the VMH and lateral hypothalamic nucleus (LH) show that the stimulation of P2Y1 receptors in these functionally antagonistic brain regions exerts an increased food intake. Hence, different signal transduction mechanisms may operate in the VMH and LH. Our assumption is supported by distinct effects of the NOS inhibitor L-NAME in these two hypothalamic nuclei. The present data suggest that ATP/ADP, acting as extracellular signal molecules in the rat brain, are involved in the regulation of food intake, possibly depending on P2Y1-receptor-mediated nitric oxide production.

Both alpha1-adrenergic and D(1)-dopaminergic neurotransmissions are involved in phenylpropanolamine-mediated feeding suppression in mice

The anorectic action of phenylpropanolamine (PPA) has been attributed to the activation of alpha1 adrenoceptors. It is unknown whether dopamine (DA) receptor subtype was involved in this action. With a treating dose higher than those used in previous reports and a testing period mainly in the dark phase of a circadian rhythm, we found that DA-ergic transmission was also involved in PPA anorexia. Pretreatment of phentolamine or prazosin could partly block PPA-induced anorexia, confirming the involvement of alpha1 adrenoceptor subtype. In addition, pretreatment of haloperidol or SCH 23390 could also partly block PPA anorexia, revealing the involvement of D(1) receptor subtype. Moreover, co-administration of prazosin and SCH 23390 could completely block PPA anorexia, confirming the co-involvement of alpha1 and D(1) receptor subtypes. These findings suggested that both subtypes of alpha1 adrenoceptor and D(1) receptor were involved in the anorectic action of PPA.

Studies on modulation of feeding behavior by atypical antipsychotics in female mice

The aim of this study was to examine the effects of different doses of typical antipsychotics, chlorpromazine (0.25-1 mg/kg) and haloperidol (0.25-1 mg/kg), and atypical antipsychotics, clozapine (0.5-2 mg/kg), olanzapine (0.25-1 mg/kg), risperidone (0.5-2 mg/kg), sulpiride (10-40 mg/kg) and dopamine D1 antagonist, SCH 23390 (0.25-1 mg/kg) on feeding behavior at different time intervals after acute administration. The study further investigated the central dopamine and serotonergic receptor involvement in clozapine-induced hyperphagia using SKF 38393, quinpirole and quipazine. Then, the authors also examined the effect of subchronic treatment for 21 days with fluoxetine on clozapine-induced hyperphagia and modulation of body weight and fat pad weights. The feeding behavior was assessed in nondeprived mice by presenting the palatable chow to different groups of mice in glass petri dishes and recording the food consumed at different time intervals. After acute administration, significant (P<.05) increase in food intake was observed at different time intervals with different doses of both typical and atypical antipsychotics. Further, clozapine-induced hyperphagia was significantly (P<.05) reversed after treatment with SKF 38393 (dopamine D1 agonist), quinpirole (dopamine D2 agonist) and quipazine (5-HT1B, 5-HT2 and 5-HT3 agonist). In subchronic study, treatment with fluoxetine (10 mg/kg) significantly (P<.05) antagonized the increase in body weight and food intake induced by clozapine (2 mg/kg). The current investigations underscore the reported increases in food intake and body weight gain observed with antipsychotics. The study further confirms the involvement of dopamine D1, D2 and serotonergic receptor involvement in clozapine-mediated hyperphagia. Further, the serotonergic agents may prove useful to counteract antipsychotic-induced obesity.

Evidence for the involvement of dopamine D(1) and D(2) receptors in mediating the decrease of food intake during repeated treatment with amphetamine

Repeated treatment with amphetamine (AMPH), a well-known anorectic agent, into animals could induce anorexia on day 1 and produce a gradual reversion of food intake (tolerant anorexia) on the following days. It is unknown whether these feeding changes are related to dopamine (DA) and/or noradrenergic neurotransmission. Thus, the present study investigated the subtype of receptor mediating AMPH-induced anorexia. Daily food intake was measured after various drugs were given. Pretreatment with haloperidol, an antagonist of DA receptors, may lead to inhibition of AMPH-induced anorexia. However, pretreatment with the alpha-adrenoceptor antagonist phentolamine, and the beta-adrenoceptor antagonist propranolol, failed to modify the action of AMPH, suggesting the involvement of DA receptors but not adrenoceptors in the action of AMPH-induced anorexia. Furthermore, pretreatment with SCH 23390 at a dose sufficient to block D(1) receptors or pimozide at a dose sufficient to inhibit D(2) receptors blocked AMPH-induced anorexia, indicating the involvement of D(1) and D(2) receptors. In a study of tolerant anorexia, repeated treatment with the D(1)/D(2) agonist apomorphine, but not the D(1) agonist SKF 38393 or D(2) agonist quinpirole, induced an AMPH-like tolerant feeding response, providing evidence for conjoint action of D(1) and D(2) receptors in the effect. The present results suggest that both D(1) and D(2) receptors are involved in anorexia and tolerant anorexia induced by chronic intermittent administration of AMPH.

Suppression of feeding-evoked dopamine release in the rat nucleus accumbens by the blockade of P(2) purinoceptors

In order to investigate whether endogenous adenosine 5'-triphosphate (ATP) is involved in the regulation of feeding, the influence of the P(2) receptor antagonist pyridoxalphospate-6-azophenyl-2', 4'-disulphonic acid (PPADS) infused into the rat nucleus accumbens on 18-h food-deprived feeding was tested. PPADS suppressed the feeding-induced dopamine release and reduced the amount of food consumed as well as the time of feeding. These results indicate that activation of P(2) purinoceptors by endogenous ATP facilitates feeding behaviour and contributes to the feeding-associated dopamine release.

Neurotransmitter system interactions revealed by drug-induced changes in motivated behavior

The present article reviews studies conducted either in collaboration with Jac Herberg, or in parallel with those studies that used consummatory behavior and responding for intracranial self-stimulation (ICSS) to investigate interactions between neurotransmitter systems. The studies reviewed include investigations of the role of dopamine in 8-OH-DPAT-induced feeding; the role of 5-HT3 receptors in the stimulant and depressant effects of nicotine on responding for ICSS; the interaction of D2 and 5-HT2 antagonists in sucrose consumption, and the differential contributions of alpha2-adrenoceptor and 5-HT2 antagonism to the rapid recovery of ICSS responding from depression produced by atypical neuroleptics. Further studies of the role of alpha2-adrenoceptor antagonism in the pattern of response decrements produced by neuroleptics on schedule-controlled responding for food confirm that the behavioral effects of monoamine interactions vary, depending on the specific receptor subtypes targeted and the behavioral paradigm employed. Consequently, the clinical relevance of findings will crucially depend on the choice of appropriate behavioral measures.

Viral gene delivery selectively restores feeding and prevents lethality of dopamine-deficient mice

Dopamine-deficient mice (DA-/- ), lacking tyrosine hydroxylase (TH) in dopaminergic neurons, become hypoactive and aphagic and die by 4 weeks of age. They are rescued by daily treatment with L-3,4-dihydroxyphenylalanine (L-DOPA); each dose restores dopamine (DA) and feeding for less than 24 hr. Recombinant adeno-associated viruses expressing human TH or GTP cyclohydrolase 1 (GTPCH1) were injected into the striatum of DA-/- mice. Bilateral coinjection of both viruses restored feeding behavior for several months. However, locomotor activity and coordination were partially improved. A virus expressing only TH was less effective, and one expressing GTPCH1 alone was ineffective. TH immunoreactivity and DA were detected in the ventral striatum and adjacent posterior regions of rescued mice, suggesting that these regions mediate a critical DA-dependent aspect of feeding behavior.

Dopamine receptor sensitive effect of dizocilpine on feeding behaviour

The effect of intracerebroventricular administration of dizocilpine on feeding behaviour and adrenal corticrotropic hormone (ACTH)-induced anorexia in elevated plus maze was examined. Dizocilpine (10, 20 and 40 nmol/rat, i.c.v.) showed a dose-dependent increase in food intake in 16 h food deprived rats. Dopamine receptor antagonists such as SCH 23390 (0.25 and 0.5 mg/kg, i.p.), pimozide (0.5 and 1 mg/kg, i.p.) and haloperidol (0.25 and 0.5 mg/kg, i.p.) dose-dependently blocked dizocilpine (40 nmol)-induced potentiation of food intake. Brain dopamine depletion by pretreatment with reserpine (5 mg/kg, i.p.) and alpha-methyl-p-tyrosine (200 mg/kg, i.p.) decreased food intake in rats. Similarly, pretreatment with reserpine and alpha-methyl-p-tyrosine (AMPT) reversed the hyperphagic effect of dizocilpine (20 and 40 nmol). Intracerebroventricular administration of ACTH (5 microgram/rat) produced significant diminution of feeding duration and increased tasting latency and feeding latency in elevated plus maze which was reversed by dizocilpine (40 nmol). SCH 23390 (0.25 mg/kg), pimozide (0.5 mg/kg) and haloperidol (0.25 mg/kg) reversed the effect of dizocilpine on ACTH-induced behaviours in elevated plus maze. The present observations support and extend the hypothesis that endogenous excitatory aminoacids (EAAs) play a role in the control of food intake. Further, dizocilpine-induced hyperphagia and dizocilpine-induced reversal of ACTH effect on feeding behaviour in elevated plus maze involve DAergic mediation.

Opioid receptor modulation of feeding-evoked dopamine release in the rat nucleus accumbens

Feeding is associated with increases in the activity of the mesolimbic dopamine (DA) system which originates in the ventral tegmental area (VTA) and projects heavily to the nucleus accumbens. The present study used in vivo brain microdialysis to assess the contribution of opioid receptors in feeding-evoked DA release in the nucleus accumbens. Feeding in 18 h food-deprived rats increased DA release by about 50% above baseline. Systemic injection of the opioid receptor antagonist naltrexone (1 mg/kg, s.c.) blocked the effect of feeding on DA release and reduced the amount of food consumed. Unilateral application of naltrexone (100 microM) in the VTA via a microdialysis probe failed to affect the DA response to feeding, the amount of food consumed, or the latency to eat. In contrast, intra-VTA naltrexone significantly reduced the effect of systemic heroin (0.5 mg/kg, s.c.) on accumbal DA release. These results indicate that: (1) opioid receptor activation is a component of the neural substrates of deprivation-induced feeding: (2) opioid receptors in the VTA do not contribute significantly to feeding-associated increases in DA release in the nucleus accumbens; and (3) heroin-induced increases in accumbal DA release are mediated, at least in part, by opioid receptors in the VTA.

Individual differences in sugar consumption following systemic or intraaccumbens administration of low doses of amphetamine in nondeprived rats

Rats exhibit individual differences in their propensity to ingest sucrose and in their feeding response to low doses of amphetamine (AMP). Rats with high baseline sugar intake (HIGH) show a decrease in sugar consumption in response to AMP, while rats with low baseline sugar intake (LOW) show an increase in consumption (33,34). At present, it is not known whether LOW and HIGH rats would be differentially responsive to higher, anorexigenic doses of AMP. Thus, the present study was developed to further determine the dose-response curve for AMP's effects on sugar consumption in LOW and HIGH rats. One group of rats received IP injections of 0.05, 0.1, and 0.2 mg/kg AMP, while a second group was administered 0.25, 0.5, and 1.0 mg/kg AMP. A third group of rats received intranucleus accumbens (Acc) microinjections of low to moderate (2.0-8.0 micrograms) doses of AMP, because evidence indicates that this may be an important site of action for AMP's effects on feeding in LOW and HIGH rats. Results showed that at low doses (< or = 0.25 mg/kg), AMP stimulated sugar consumption in LOW rats and either had no effect or inhibited consumption in HIGH rats. At doses greater than 0.25 mg/kg, AMP inhibited sugar consumption in both LOW and HIGH rats. Furthermore, intra-Acc administration of AMP stimulated sugar intake in LOW rats and produced a slight, but nonsignificant, decrease in consumption in HIGH rats. Taken together, these results show that LOW and HIGH rats exhibit individual differences in their feeding response to low but not moderate to high doses of AMP. Furthermore, the evidence indicates that the Ace is an important site for AMP's facilitatory effect on sugar consumption in LOW rats.

The pedunculopontine tegmental nucleus: where the striatum meets the reticular formation

The pedunculopontine tegmental nucleus (PPTg) contains a population of cholinergic neurons (the Ch5 group) and non-cholinergic neurons. There appears to be functional interdigitation between these two groups, which both have extensive projections. The principal ascending connections are with thalamic nuclei and structures associated with the striatum, including the substantial nigra pars compacta. The descending connections are with a variety of nuclei in the pons, medulla and spinal cord, concerned with autonomic and motor functions. In the past, emphasis has been laid on the role of the PPTg in locomotion and behavioural state control. In this review, we emphasise the role of the PPTg in processing outputs from the striatum. The non-cholinergic neurons receive outflow from both dorsal and vental striatum, and lesions of the PPTg disrupt behaviour associated with each of these. Our review indicates that the PPTg is less concerned with the induction of locomotion and more concerned with relating reinforcement (information about which comes from the ventral striatum) with motor output from the dorsal striatum. The conclusions we draw are: (1) the PPTg is an outflow system for the striatum, but also forms a 'subsidiary circuit', returning information to striatal circuitry; in this, the PPTg has an anatomical organisation that resembles that of the substantia nigra. (2) As well as a role in the mediation of REM sleep, cholinergic PPTg neurons have an important role in the waking state, providing feedback into the thalamus and striatum. (3) The precise function of the computations performed on striatal outflow by the PPTg is uncertain. We discuss whether this function is complementary (parallel to other routes of striatal outflow), integrative (modifying other forms of striatal outflow) or both.

Effect on rat feeding behavior of two selective D2 dopamine agonists

B-HT 958 and SND 919, two selective agonists at D2 dopamine receptors, were examined for their influence on the feeding behavior of fasted rats. When food intake was determined in the rat's individual home cage, it was found to be reduced by both drugs at low sedative doses during the first hour after treatment and by SND 919 at the highest dose (which also elicits stereotypy) only 24 h later. However, SND 919 and B-HT 958 had no significant effect on feeding evaluated according to the X-maze and tube feeding tests. Analysis of the results, seen in the context of other behavioral signs produced by the drugs, suggests that data on feeding may vary depending on the experimental model used and can be modified by extraneous factors that interfere with a specific effect on food intake.

The effect of B-HT 920, a dopamine D2 agonist, on bar-press feeding in the monkey

Although the dopamine (DA) system has been shown to regulate food intake, the function of the DA receptor subtypes on behavior still remains to be elucidated. In the present study, we examined the effect of B-HT 920, a selective agonist of DA D2 receptors that preferentially affect presynaptic autoreceptors, on both food consumption and execution of a high fixed-ratio bar-press task for food reward in monkeys. Two kinds of bar-press task were used: 1) a cue-triggered bar-press task during the first 40 trials, and 2) a self-paced bar-press task in which the monkeys freely performed bar-press trials until they were satiated. A SC injection of B-HT 920 (25 micrograms/kg) increased food consumption in the home cage. The same facilitatory effect on food consumption was also observed in the operant task condition. During the cue-triggered bar-press task, however, both the latency of the bar-press responses to a cue light and the time required to complete the bar-press trials were prolonged after the injection of B-HT 920. The results suggest that the activation of D2 autoreceptors suppresses the operant food acquisition behavior and increases food consumption through an inhibition of the satiety mechanism rather than an activation of any hunger-related drive.

Nucleus accumbens dopamine-CCK interactions in psychostimulant reward and related behaviors

The present paper provides an overview of dopamine (DA) and cholecystokinin (CCK) mechanisms that contribute to psychostimulant reward-related behaviors. Three different behavioral paradigms are focused on: intravenous psychostimulant reward, psychostimulant-induced locomotor activity, and psychostimulant-induced feeding. Based on evidence derived from these different behavioral paradigms, this paper reviews data indicating that nucleus accumbens CCK and DA play an important role in mediating reward. Neurobiological mechanisms are proposed to explain the functional relationship between CCK and DA in the nucleus accumbens.

Long-continuous observation of the effects of methamphetamine on wheel-running and drinking in mice

1. Effects of methamphetamine (MAP) on wheel-running and drinking in mice, housed under 12-hr light-dark schedule (light period; 06:00-18:00), were investigated through long-continuous observation. 2. MAP (1, 2 and 4 mg/kg, s.c.) acutely increased the wheel-running and drinking for 2-4 hr in a dose-dependent manner after the administration at 11:00, midpoint of light period. 3. MAP administered at 11:00 sub-acutely suppressed the spontaneous increment during dark period (18:00-06:00) in both the behaviors. 4. Many factors, such as the time-of-day and interval of the administration as well as the dose administered, affected the behavioral suppression induced by MAP. 5. In addition to these findings, the wheel-running and drinking during the light period increased even on the days without MAP administration. 6. These results suggest that MAP have not only acute stimulant and sub-acute depressant effects, but also long-lasting effects.

Amphetamine-induced modification of quinine palatability: analysis by the taste reactivity test

The effects of low doses of d-amphetamine (0.25-0.5 mg/kg, IP) on taste reactions elicited by quinine solutions in a 5-10-min taste reactivity test were assessed in a series of three experiments. Amphetamine consistently suppressed aversive reactions elicited by quinine solutions. The results suggest that amphetamine, like morphine, attenuates the aversiveness of the taste of quinine solution.

Effects of variation in chronic dose of cocaine on contingent tolerance as assessed in a milk-drinking task

Tolerance to the suppressive effects of cocaine on milk drinking by rats was studied using a contingent tolerance experimental design. Three separate groups (n = 6) of rats received 8.0, 16.0, or 32.0 mg/kg cocaine daily 15 min before a 15-min period of access to sweetened condensed milk for 20 days. Three additional groups of six rats each received the same chronic doses 15 min after access to milk. Milk, water, and food intake as well as body weight were measured daily. Tolerance effects were assessed by comparing initial acute dose-effect determinations with a probe dose-effect redetermination in which all rats again received doses of cocaine pre-session after having experienced the differential pre- or post-session chronic treatment. Behavioral tolerance on the milk intake measure was observed for the 8.0 mg/kg and 16.0 mg/kg doses, but not for the 32.0 mg/kg chronic treatment, even though the latter group exhibited evidence of tolerance in the water intake measure. Chronic treatment with 8.0 and 16.0 mg/kg produced different outcomes in that chronic exposure to 16.0 mg/kg in the presence of milk resulted in generalization of tolerance to both a lower (8.0 mg/kg) and a higher dose (32.0 mg/kg), but the group receiving 8.0 mg/kg did not exhibit generalization of tolerance to higher doses. Modest sensitization effects were observed in the rats treated post-session with either 8.0 or 16.0 mg/kg.(ABSTRACT TRUNCATED AT 250 WORDS)

A comparison of behaviour following stimulation of the anterior substantia nigra by direct cholinergic agonists and anticholinesterases

Microinjections of carbachol, a muscarinic cholinergic receptor agonist, into the anterior substantia nigra increase feeding, drinking and sexual behaviour if there is a pre-existing tendency to respond and a low baseline rate of behaviour. The present experiment was undertaken to compare the effects of carbachol with other cholinergic stimulants. Groups of 6-12 satiated rats received 0.5 microliter microinjections into the anterior substantia nigra of 0.1-5.0 micrograms carbachol, 0.1-5.0 micrograms nicotine, 2.5-10.0 micrograms eserine, and 1.25-5.0 micrograms or 0.1-1.0 microgram neostigmine (each dissolved in sterile saline) and the effects on feeding, drinking, locomotion, grooming, rearing and sniffing were examined. Carbachol, nicotine and low doses of neostigmine stimulated eating in a dose-dependent manner. The increased feeding following neostigmine was over a shorter time-period than following carbachol or nicotine. Neither carbachol nor nicotine had any significant effect on behaviour other than eating. The higher doses of neostigmine increased the frequency of sniffing and rearing, but not eating, and no dose of eserine had a clear effect on behaviour. These data are discussed in terms of their relationship to the cholinergic input to substantia nigra which excites pars compacta dopamine-containing neurones.

Individual differences in the feeding effects of amphetamine: role of nucleus accumbens dopamine and circadian factors

Evidence indicates that amphetamine (AMP) affects feeding in a baseline-dependent fashion and that the nucleus accumbens (Acc) is an important site of action for AMP's effects on feeding. Experiment 1 examined the contribution of Acc-dopamine (DA) mechanisms to the baseline-dependent feeding effects of a 0.125 mg/kg dose of AMP using intra-Acc administrations of cis-flupenthixol (FLU). Results showed that there was an inverse relation to AMP, such that AMP stimulated feeding in animals with high baseline intake. Intra-Ace FLU administration reversed the stimulatory but not the inhibitory effect of AMP. Further, intra-Acc FLU attenuated baseline feeding in high but not low baseline feeders. Experiment 2 sought to determine whether AMP would affect feeding in a baseline-dependent manner when administered in the dark photoperiod of the rat circadian cycle, when rats do most of their feeding. To this end, rats were administered three doses (0.05,0.01, and 0.25 mg/kg) of AMP in the dark photoperiod and the intake of sugar monitored. Results showed that in low baseline feeders, AMP stimulated intake at lowest dose and had no effect at higher doses. In high baseline feeders, AMP inhibited intake in a dose-dependent manner. Taken together, these results further establish that AMP affects feeding in a baseline-dependent fashion. Moreover, the similar effects of AMP across the light and dark photoperiods suggest that a straightforward rate-dependency interpretation is not adequate. Finally, it is speculated that Acc-DAergic activity may play a role in the observed differences in baseline intake levels and in the response to AMP.

Effects of the dopamine D2 agonists lisuride and CQ 32-084 on rat feeding behaviour

The influence on rat-feeding behaviour of lisuride and CQ 32-084, agonists at dopamine D2 receptors, was examined using two procedures. In a first series of experiments, the apparatus was an X-maze baited with food pellets where individual fasted rats were observed for 5 min. A number of parameters were recorded: latency to tasting and feeding, interval between tasting and feeding, total feeding time, and total grooming time. Lisuride (0.05 and 0.1 mg/kg) and CQ 32-084 (0.05 and 0.5 mg/kg) behaved as stimulants of eating; lisuride (0.4 mg/kg) inhibited the phenomenon. Both drugs always antagonized grooming. Subsequently, when food intake was determined in the home cages of fasted animals lisuride reduced feeding at all doses during the first hour after treatment, while CQ 32-084 had no effect. The data show that the two compounds display different activity on ingestive behaviour according to the dose and experimental model used. Discussion centres on the possible dependence of feeding enhancement in the X-maze on the anxiolytic activity exerted by low D2 autoreceptorial doses.

Morphine place conditioning is differentially affected by CCKA and CCKB receptor antagonists

In the present study we have examined the interaction between the selective cholecystokinin (CCK)A and CCKB receptor antagonists, devazepide and L365-260 on morphine conditioned place preference (CPP). Using an unbiased procedure, morphine (1.5 mg/kg) produced a reliable CPP which was observed irrespective of the conditioning compartment type. Pretreatment with devazepide (0.001-0.01 mg/kg s.c.) produced a dose related attenuation of this response. At higher doses (0.1-1 mg/kg) this antagonism became variable and dependent on the training compartment with blockade only observed when conditioning was to the white/rough textured environment. This profile has also been reported for the serotonin (5-HT)3 receptor antagonist ondansetron. The CCKB antagonist L365-260 (0.000001-0.01 mg/kg) failed to antagonize the morphine CPP, if anything a mild potentiation was observed. To study this further we examined the interaction between L365-260 (0.01 mg/kg) and a subthreshold dose of morphine (0.3 mg/kg). At these doses neither drug elicited CPP, however when co-administered a significant CPP was recorded. Finally, L365-260 at 1 mg/kg induced a mild but significant CPP when administered alone. These results suggest a differential role of CCK receptor subtypes on reward-related behaviour and complement previous studies suggesting bimodal effects of CCK systems on mesolimbic dopamine function.

N-methyl-D-aspartate lesions of the lateral hypothalamus do not reduce amphetamine or fenfluramine anorexia but enhance the acquisition of eating in response to tail pinch in the rat

These experiments examine the acquisition of tail pinch-induced eating and responses to the anorectic agents d-amphetamine and d,l-fenfluramine by rats bearing N-methyl-D-aspartate (NMDA) lesions of the lateral hypothalamus. Lesioned rats lost weight following surgery but had no significant eating or drinking difficulties in the home cage (Clark et al. 1990). The acquisition of eating in response to tail pinch was enhanced in lateral hypothalamic-lesioned rats: they ate on earlier test sessions than controls and less pressure was required to elicit eating. Home cage food intake over the period when tail pinch was being examined was not affected by the lateral hypothalamic lesions. There were no significant differences between lateral hypothalamic-lesioned and control rats in terms of their anorectic responses to either d-amphetamine or d,l-fenfluramine, though the lesioned rats had a lower baseline intake. These data suggest that the lateral hypothalamus is not an important site for the mediation of amphetamine or fenfluramine anorexia but is involved in the acquisition of tail pinch-induced eating. The disinhibition of responding to tail pinch by lateral hypothalamic lesions is discussed in terms of the possible role the lateral hypothalamus plays in regulating cortical activity. The role of the medial hypothalamus and non-hypothalamic systems in the response to anorectic drugs and tail pinch is discussed.

Possible involvement of dopamine D-1 and D-2 receptors in diazepam-induced hyperphagia in rats

Possible involvement of dopamine receptors in diazepam-induced (1 mg/kg, subcutaneous (sc] hyperphagia was studied in nondeprived rats. Pretreatment with the selective D-1 antagonist, SCH23390 (0.03 mg/kg, sc) inhibited diazepam-induced hyperphagia. In addition, pretreatment with the preferential D-2 antagonists, haloperidol (0.1 to 0.3 mg/kg, sc) and clebopride (0.1 to 0.3 mg/kg, sc) inhibited diazepam-induced hyperphagia in a dose-dependent manner. Pretreatment with co-administration of SCH23390 (0.1 mg/kg, sc) and clebopride (0.03 mg/kg, sc) completely inhibited this hyperphagia. The selective D-2 antagonist, sulpiride (40 mg/kg, sc) and the peripheral D-2 antagonist, domperidone (10 mg/kg, sc) did not affect diazepam-induced hyperphagia. However, sulpiride (10 micrograms, icv) or domperidone (2 micrograms, icv) administered centrally inhibited this hyperphagia. The highest dose of haloperidol (0.3 mg/kg, sc) or clebopride (0.3 mg/kg, sc) and higher doses of SCH23390 (0.01 and 0.03 mg/kg, sc) or SCH23390/clebopride (0.01/0.03 and 0.01/0.1 mg/kg, sc) tended to decrease spontaneous feeding in non-deprived rats. In addition, the highest dose of haloperidol, clebopride or SCH23390/clebopride inhibited spontaneous feeding in deprived rats. Interestingly, diazepam-induced hyperphagia was inhibited significantly by doses of haloperidol (0.1 mg/kg, sc), clebopride (0.1 mg/kg, sc) and SCH23390/clebopride (0.003/0.03 and 0.003/0.1 mg/kg, sc) which did not affect spontaneous feeding in non-deprived or deprived rats. Pretreatment with alpha-methyl-p-tyrosine (40 mg/kg, IP x 2, 6 and 2 h prior to diazepam administration) failed to inhibit this hyperphagia. Furthermore, pretreatment with a large dose of haloperidol (5 mg/kg, sc, 4 days before diazepam administration) augmented the sub-hyperphagic effect to diazepam (0.5 mg/kg, sc). Thus, these findings suggest that hyperphagia to diazepam is mediated in part by both dopamine D-1 and D-2 receptors in non-deprived rats.

Opiate antagonists inhibit feeding induced by 8-OH-DPAT: possible mediation in the nucleus accumbens

Previous work has shown that the 5-hydroxytryptamine (5-HT)1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) elicits a variety of behaviours, including feeding in rats. These effects are accompanied by reduced 5-HT neurotransmission resulting from activation of somatodendritic 5-HT receptors located in the midbrain raphe nuclei. Dopamine antagonists injected either peripherally or into the nucleus accumbens reverse 8-OH-DPAT-induced feeding. Thus a facilitation of dopamine activity, secondary to reduced 5-HT activity, may be involved in mediating 8-OH-DPAT-induced feeding. Opiate antagonists have been shown previously to reduce several dopamine-dependent behaviours including feeding induced by dopaminergic drugs, tail pinch and electrical brain stimulation. Therefore experiments were conducted to assess the effects of opiate antagonists on feeding induced by peripheral, and raphe injection of 8-OH-DPAT in free-feeding rats. Following SC injection naloxone (0.1-10 mg/kg) dose-dependently reduced the feeding response induced by 100 micrograms/kg 8-OH-DPAT (SC). The lowest effective dose of naloxone was 1 mg/kg. This dose of naloxone also suppressed feeding induced by 8-OH-DPAT injected into either the dorsal (1 microgram) or median (0.5 micrograms) raphe. Microinjecting 2 micrograms naloxone together with 8-OH-DPAT into either of these sites failed to prevent the increased feeding. These results indicate that the effects of naloxone are mediated at sites distal to the raphe nuclei. One possible site may be the nucleus accumbens, since methyl-naltrexone (0.3, 1 or 3 micrograms) injected into this site blocked the feeding responses to intra-raphe 8-OH-DPAT.(ABSTRACT TRUNCATED AT 250 WORDS)

Dopamine receptor blockade in nucleus accumbens or caudate nucleus differentially affects feeding induced by 8-OH-DPAT injected into dorsal or median raphe

The 5-hydroxytryptamine (5-HT)1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) elicits a variety of behaviours including feeding in rats. These effects are accompanied by a reduction in 5-HT neurotransmission resulting from activation of somatodendritic 5-HT receptors located in the midbrain raphe nuclei. Previous work showing that dopamine receptor antagonists attenuate 8-OH-DPAT-induced feeding indicates that a facilitation of dopamine activity, secondary to reduced 5-HT activity, is involved in the expression of this effect. Microinjection studies were conducted to explore further the nature of this 5-HT-dopamine interaction. Injection of 8-OH-DPAT (0.125-2 micrograms) into either dorsal or median raphe induced dose-dependent increases in 1 h food intake in non-deprived rats. Pretreatment with haloperidol (0.05 and 0.1 mg/kg s.c.) attenuated the effect induced by median raphe 8-OH-DPAT (0.5 microgram) complementing previous results with dorsal raphe 8-OH-DPAT. The feeding resulting from dorsal raphe (1 microgram) or median raphe (0.5 microgram) 8-OH-DPAT was attenuated by alpha-flupenthixol (1.25 and 2.5 micrograms) injected into the nucleus accumbens. alpha-Flupenthixol in either the dorsolateral or ventrolateral aspects of the caudate nucleus attenuated also the feeding response to dorsal raphe, but not median raphe, 8-OH-DPAT. However, alpha-flupenthixol in the dorsomedial caudate failed to alter feeding resulting from dorsal raphe 8-OH-DPAT.(ABSTRACT TRUNCATED AT 250 WORDS)

5-HT1A agonists and dopamine: the effects of 8-OH-DPAT and buspirone on brain-stimulation reward

Two specific 5-HT1A agonists, 8-OH-DPAT (0-300 micrograms/kg), and buspirone (0-3.0 mg/kg), were tested on variable-interval, threshold-current self-stimulation of rat lateral hypothalamus. Buspirone produced a prolonged monotonic depression of responding, whereas the effects of 8-OH-DPAT were biphasic: 3.0 micrograms/kg produced a sustained enhancement of responding while higher doses (100-300 micrograms/kg) produced a relatively short-lasting depression. This biphasic pattern parallels previously reported effects of 8-OH-DPAT on food intake and on various other behaviours. Threshold-current self-stimulation is highly sensitive to alterations in dopaminergic transmission but relatively insensitive to changes in 5-HT. Thus the facilitatory effect of low-dose 8-OH-DPAT seems most plausibly interpreted in terms of enhanced dopaminergic transmission. This could be brought about by 5HT1A autoreceptor-mediated inhibiton of 5-HT release and consequent disinhibition of dopaminergic transmission. Depression of self-stimulation by higher doses of 8-OH-DPAT may reflect the activity of 8-OH-DPAT at postsynaptic 5-HT receptors, with consequent inhibition of DA transmission. Suppression of responding after buspirone at all doses tested may reflect the action of this compound as a partial agonist at postsynaptic 5-HT receptors, and/or its effects on other systems.

Evaluation of dopamine receptor involvement in rat feeding behaviour

1. The anorectic effect of dopamine agonists and antagonists were studied in rats. 2. Dopamine agonists bromocriptine, quinpirole or SKF 38393 treatment induced, a dose-dependent anorexia in rats. 3. Anorectic effect of bromocriptine was decreased in animals pretreated with pimozide (D-2 antagonist), but not by sulpiride (D-2 antagonist) or SCH 23390 (D-1 antagonist) pretreatment. 4. Anorexia induced by quinpirole was decreased by sulpiride or pimozide, but not by SCH 23390 administration. 5. While sulpiride and SCH 23390 failed to antagonize the anorectic response of SKF 38393, methergoline (5-HT antagonist) decreased anorexia induced by the drug. 6. A combination of quinpirole with SKF 38393 did not elicit potentiated anorectic response. 7. Decrease in food intake induced by bromocriptine, quinpirole or SKF 38393 was potentiated in reserpinized animals, although single administration of reserpine also induced a marked decrease in feeding. 8. Single administration of sulpiride, pimozide or methergoline did not change the feeding behaviour of rats, but SCH 23390 induced anorexia. 9. It is concluded that D-2 activation may induce inhibition of feeding and anorexia induced by SKF 38393 may be mediated through serotonergic mechanism(s).

Cholinergic stimulation of substantia nigra: effects on feeding, drinking and sexual behaviour in the male rat

Previous studies have shown that cholinergic stimulation of the substantia nigra increases food intake but not other activities. The present experiments were undertaken to determine whether or not activities other than feeding could be stimulated if conditions were appropriate. Microinjections of the cholinergic agonist carbachol (0.5 micrograms/0.5 microliters each side) bilaterally into substantia nigra increased the consumption of dry spaghetti, and, in subsequent tests, changed sexual behaviour in male rats. Ejaculation, mount and intromission latencies were unaffected but intromission frequency (though not mount frequency) was reduced following cholinergic stimulation (experiment 1). In a second experiment, an increase in the consumption of 2.0% saccharin solution and lab chow was stimulated by intranigral carbachol while the intake of tap water, and locomotion, gnawing, grooming, rearing and sniffing were all unaffected. These data indicate that cholinergic stimulation of substantia nigra can affect activity for which there is a pre-existing tendency, regardless of its form. A possible role for nigral acetylcholine in the control of pars compacta dopamine containing neurones is discussed.

Facilitation and inhibition of feeding by a single dose of amphetamine: relationship to baseline intake and accumbens cholecystokinin

Amphetamine (AMP) administered in high doses suppresses feeding. However, in low doses AMP has been shown to both suppress and facilitate feeding. Further, there is some indication of individual differences in the feeding response to low doses of AMP. Evidence indicates that AMP's effects on feeding are dopamine-mediated and that the nucleus accumbens (Acb) may be an important site of action. Of interest here is the fact that CCK terminals exist within the Acb and CCK modulates DA activity. Experiment 1 investigated the effects of intra-Acb CCK administration as a function of individual differences in the feeding response to a low dose of systemic AMP. Results indicate that response to AMP was baseline dependent. AMP stimulated feeding in low baseline feeders and suppressed feeding in high baseline feeders. Intra-Acb CCK blocked the AMP-induced increase in feeding but not the AMP-induced anorexia. In experiment 2, the effects of intra-Acb CCK administration on baseline feeding were assessed. Intra-Acb CCK suppressed baseline feeding, but only when there was a high level of intake. It is speculated that Acb-DAergic activity may play a role in the observed feeding effects of both AMP and CCK.

A comparison of benzodiazepine, serotonin, and dopamine agents in the taste-reactivity paradigm

Previous studies have shown that rats' positive, palatability-dependent consummatory reactions to infused tastes are selectively facilitated by a benzodiazepine agonist (chlordiazepoxide), and that this effect can be blocked by the coadministration of benzodiazepine antagonists (e.g., Ro 15-1788). The purpose of the present study was to determine whether agents acting at other receptor sites (dopaminergic, serotonergic), which have been shown to modulate food consumption, might also modify rats' palatability-dependent reactivity to infused tastes. In this experiment, the benzodiazepine agonist, diazepam, facilitated positive palatability reactions, while dopaminergic agents (haloperidol, apomorphine, amphetamine) had no significant effects on either positive or aversive reactions. The putative 5-HT1A agonists, buspirone and gepirone, had a general inhibitory action on both positive and aversive palatability reactions. These results are surprising in view of the effects of serotonergic and dopaminergic agents on food and fluid intake. Our results suggest that the benzodiazepine receptor system may play a special role in the neural control of appetite through its enhancement of the positive palatability of tastes. Dopamine systems, by contrast, appear to control food intake by modulating processes that are independent of food affect evaluation.

Dorsal raphe microinjection of 5-HT and indirect 5-HT agonists induces feeding in rats

Previous work has shown that 5-hydroxytryptamine (5-HT) receptor agonists such as 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) reduce 5-HT neurotransmission and induce feeding in rats. The effects of 8-OH-DPAT appear to be mediated in part in the dorsal raphe nucleus by serotonergic somatodendritic autoreceptors which normally regulate impulse flow in 5-HT dorsal raphe neurons. The present experiments sought to examine whether suppression of dorsal raphe serotonergic neural activity induced by exogenously applied, or endogenously released 5-HT would increase feeding. Free-feeding rats were microinjected in the dorsal raphe with 5-HT, the 5-HT releasing compound d-fenfluramine, the 5-HT re-uptake inhibitor zimelidine, or the type-A monoamine oxidase inhibitor brofaromine. Dose dependent increases in food intake over a 1 h period were found following treatment with 5-HT and the three indirectly acting compounds. Thus, increased serotonergic activity within the dorsal raphe increases feeding, presumably by inhibiting the activity of dorsal raphe 5-HT neurons. In addition the effects of 5-HT were blocked by pretreatment with haloperidol, indicating the involvement of a dopaminergic mechanism in mediating the effects of feeding of a suppression in dorsal raphe 5-HT neural activity. The results are discussed in terms of the general role which serotonergic neurons arising from the dorsal raphe may play in behavioural inhibition.

The involvement of 5-hydroxytryptaminergic and dopaminergic mechanisms in the eating induced by buspirone, gepirone and ipsapirone

1. The roles of 5-hydroxytryptamine (5-HT) and dopamine systems in mediating the increased feeding induced by buspirone, gepirone and ipsapirone were investigated. 2. All three compounds induced dose-dependent increases in food intake when administered subcutaneously to free feeding rats. Buspirone was effective over a narrower dose range than either gepirone or ipsapirone, and the maximal effect observed was smaller than the effects elicited by gepirone and ipsapirone. 3. Depletion of brain 5-HT with parachlorophenylalanine (PCPA) prevented the effects of equi-effective doses of gepirone (2.5 mg kg-1) and ipsapirone (2.5 mg kg-1), but failed to prevent buspirone (1 mg kg-1)-induced eating. Thus buspirone does not appear to interact with 5-HT systems to elicit feeding. 4. Gepirone (0.2 micrograms) and ipsapirone (0.04 and 0.2 micrograms) increased food intake when injected into the dorsal raphé nucleus (DRN), presumably by inhibiting the activity of DRN 5-hydroxytryptaminergic afferents. Buspirone (0.04-5 micrograms) was ineffective when injected into the DRN. 5. Pretreatment with haloperidol (0.1 mg kg-1, 30 min) significantly attenuated the effects of equi-effective doses of buspirone, gepirone and ipsapirone, indicating that these drugs interact with dopaminergic systems to increase feeding. 6. Previously it has been shown that each of these drugs increases striatal dopamine activity. Increased dopaminergic neurotransmission in the striatum induces a general behavioural activation, which under certain conditions facilitates feeding. It is possible that this mechanism underlies the behavioural effects of buspirone, gepirone and ipsapirone. The effects of gepirone and ipsapirone probably involve an indirect action to inhibit the activity of DRN 5-hydroxytryptaminergic afferents, whereas buspirone interacts directly with dopaminergic systems.

Amphetamine- and morphine-induced feeding: evidence for involvement of reward mechanisms

The present study examined the possibility that the increased feeding found following central and peripheral administrations of low doses of d-amphetamine (AMP) and morphine (MOR) may involve central reward mechanisms. In order to examine this possibility, the effects of these drugs on food selection and intake of foods that varied in palatability and nutritive content were determined. In addition, the importance of the nucleus accumbens (ACB), a critical structure for AMP and MOR reward, in these effects was determined. Results indicated that MOR increased the intake of preferred food regardless of nutritive content. In contrast, AMP was most effective at increasing the intake of preferred foods which contained carbohydrates. These effects were observed following systematic or intra-ACB administration of low doses of MOR and AMP. Together these findings implicate reward mechanisms in the expression of MOR- and AMP-induced feeding. It is further suggested that the feeding effects of MOR and AMP can be differentiated in paradigms where animals have a choice of several foods which may vary in palatability and/or nutritive content. The relevance of the present findings for our understanding of which elements of food and feeding behavior are coupled with ACB reward signals is also discussed.

A pharmacological analysis of the eating response induced by 8-OH-DPAT injected into the dorsal raphé nucleus reveals the involvement of a dopaminergic mechanism

Direct injection of the 5-hydroxytryptamine (5-HT) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) into the dorsal raphé nucleus (DRN) dose dependently increased food intake in free feeding rats. The hypothesis that this effect is mediated by 5-HT1A receptors was tested by investigating the abilities of the putative 5-HT1A antagonists metergoline, propranolol and spiperone to prevent 8-OH-DPAT-induced eating. Metergoline failed to affect 8-OH-DPAT-induced eating when injected either peripherally or into the DRN. Peripherally injected propranolol and spiperone prevented 8-OH-DPAT-induced eating, but these drugs were ineffective when injected into the DRN. These results indicate that 8-OH-DPAT-induced eating may not involve 5-HT1A receptors within the DRN. The ability of peripherally injected spiperone to prevent the eating response to 8-OH-DPAT reflects its dopamine blocking activity since haloperidol was an effective antagonist of 8-OH-DPAT-eating. This result may indicate that 8-OH-DPAT produces a general behavioural activation by reducing the inhibitory influence which 5-HT normally exerts over the nigrostriatal dopamine pathway, and that this behavioural activation is expressed as eating when food is the most salient goal object present.

Amphetamine microinjections into distinct striatal subregions cause dissociable effects on motor and ingestive behavior

The mammalian striatum, although cytoarchitecturally consistent throughout its extent, is considered heterogeneous with regard to functional subregions. The present study investigated the behavioral effects of amphetamine microinjections into specific subregions within the striatum. These three sites, the nucleus accumbens (N.Acc), ventrolateral striatum (VLS) and dorsolateral striatum (DLS), were selected on the basis of their differential afferent projections. Three groups of rats were implanted with guide cannulae aimed at these sites, and were tested in their home cages following intrastriatal administration of saline, 0.1, 1.0, or 5.0 micrograms amphetamine (0.5 microliters bilaterally). Spontaneous motor and ingestive behaviors (the rats were maintained ad libitum) were observed and recorded over a 40-min session. Amphetamine injected into the N.Acc produced a dose-dependent increase in locomotion and rearing and decreased the average duration of rears. No effects were found on feeding or drinking. Amphetamine injected into the VLS had no overall effects on motor behavior, except to decrease locomotion and rearing in the first 10 min following the high dose. During this period, however, VLS amphetamine-treated animals showed increased levels of feeding, with no effects on drinking. At the higher doses of amphetamine infused into the VLS, some rats showed a marked but short-lasting stereotyped biting of the forepaws. Amphetamine injected into the DLS resulted in no measurable changes in behavior. Findings are interpreted as evidence for the diversity of the striatal dopamine system, based on its limbic and cortical connections, and suggest in particular that the ventrolateral striatum may critically mediate oral behavior.

Blockade of 8-OH-DPAT-induced feeding by dopamine antagonists

Feeding elicited by the 5HT1A agonist 8-OH-DPAT was blocked by pretreatment with the DA antagonists SCH-23390 and sulpiride, in two experiments conducted in non-deprived rats and in three experiments conducted after 4 h food deprivation. In deprived animals, 8-OH-DPAT prolonged the initial period of feeding. However, in non-deprived animals, 8-OH-DPAT delayed the onset of eating, and suppressed post-prandial resting; both SCH-23390 and sulpiride restored the normal pattern of behaviour. All three drugs suppressed grooming. The results suggest that 8-OH-DPAT elicits feeding by a secondary disinhibition of activity postsynaptic to DA neurons. The consequences of this mechanism for the interpretation of 8-OH-DPAT-induced feeding are discussed.

Screening of pharmacological agents given peripherally with respect to TCDD-induced wasting syndrome in Long-Evans rats

A salient sign of fatal 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication is dramatic body weight loss accompanied by hypophagia. Yet, the nature of this wasting syndrome is unknown. As all of the current leptogenic (weight reducing) drugs exert their action by affecting aminergic neurotransmission, this study set out to screen the reversibility of TCDD-induced anorexia with the following agents modulating aminergic neurotransmission: amphetamine, amperozide, chlordiazepoxide, clonidine, haloperidol, morphine, PCPA, phenoxybenzamine, reserpine and sotalol. In addition, dexamethasone, indomethacin, and insulin were included in the drug battery. The agents were administered subcutaneously to adult male Long-Evans rats over a period lasting from 3 to 14 days. Half of each drug group was concomitantly exposed to a lethal dose of TCDD (20 micrograms/kg). None of the regimens were able to mitigate the wasting syndrome. TCDD proved to markedly diminish the nocturnal feed intake while practically sparing daytime feed consumption. Insulin increased the daytime feeding of TCDD-exposed rats, and the termination of treatment resulted in almost total aphagia in this group. Amphetamine, dexamethasone, PCPA, and reserpine caused weight loss in drug control rats and aggravated the action of TCDD. However, clonidine had no effect on the weight of control rats but accelerated weight decline in TCDD-cotreated animals. TCDD seemed to have a somewhat minor influence on drinking than on feeding. Clonidine stimulated water intake in controls but not in TCDD-exposed rats. These results suggest that aminergic neurotransmission is not specifically or crucially affected by TCDD, but further studies are needed to confirm this conclusion.

Concurrent facilitory and inhibitory effects of amphetamine on stimulation-induced eating

At low doses (0.125 and 0.25 mg/kg, i.p.), amphetamine facilitated eating induced by lateral hypothalamic electrical stimulation. It decreased the frequency threshold for the behavior and it increased the probability of eating across a range of suprathreshold stimulation frequencies; it also accelerated eating, decreasing the average time to eat three 45-mg food pellets across the range of stimulation frequencies tested. At high doses (1.0 and 2.0 mg/kg), amphetamine increased the frequency threshold and decreased the probability of eating across the range of suprathreshold stimulation frequencies; on those trials where eating was observed, however, even these doses of amphetamine accelerated feeding. Several lines of evidence suggest that amphetamine influences feeding through multiple mechanisms, and that present data may be explained by independent facilitory and inhibitory mechanisms, with the inhibitory mechanism less sensitive to low doses but generally dominant when the two mechanisms are both activated by higher doses. Another possibility is that the well-known anorexic effects of amphetamine result at least in part from over-stimulation of the same mechanism as is involved in the more subtle facilitory effects of the drug.

[Pharmacological and molecular aspects of the regulation of eating behavior. With special reference to the role of catecholamines and effects of amphetamine]

Among the numerous endogenous substances involved in the regulation of feeding behaviours, the catecholamines are in the front rank. The numerous studies devoted to this aspect of catecholamines emphasize the importance and complexity of their intervention. Depending on the cerebral structures on which they act and on whether noradrenaline or dopamine are concerned, orexigenic or anorexigenic effects have been described. Alpha-2 and beta adrenergic receptors as well as D1 and D2 dopaminergic receptors participate in these effects. Amphetamine, which is an indirect catecholaminergic agonist, mobilizes neuronal catecholamines and fosters their various effects. Moreover, it exercises direct effects by its association with sites borne by glycaemia-sensitive neurons. This target seems to be common to a wide variety of anorectic agents. They are thought to reproduce on this hypothalamic "glucostat" the effect of a high blood glucose level, thus triggering off signals of satiety. In this unifying hypothesis, the diverse pharmacological profiles these agents are known to possess would result from associated properties.

Role of dopamine D-1 and D-2 receptor subtypes in mediating dopamine agonist effects on food consumption in rats

The effects of selective D-2 and D-1 dopamine (DA) receptor agonists on food consumption were investigated in free-feeding rats. A selective D-2 receptor agonist, (+)-4-propyl-9-hydroxynaphthoxazine (PHNO), increased the consumption of standard food pellets in the dose range of 7.5-120 micrograms/kg, while SKF 38393 (5.0 mg/kg), a selective D-1 receptor agonist, decreased food pellet intake. The increase in food pellet intake produced by PHNO was blocked by haloperidol (an antagonist relatively selective for the D-2 receptor at the dose used, 0.05 mg/kg) and SCH 23390 (20 micrograms/kg, a D-1 receptor selective antagonist). Increasing "arousal" by disturbance associated with repeated food weighing also increased food pellet consumption, but did not diminish PHNO-elicited feeding. However, the same range of doses of PHNO (7.5-120 micrograms/kg) which increased food pellet intake decreased consumption of a liquid diet, and had no overall effect on a highly palatable liquid diet. The increase in consumption of solid food induced by PHNO appears to be secondary to enhancement of chewing behaviors. In contrast, the decrease in food intake induced by SKF 39393 may be due to a direct action of the drug on neural feeding mechanisms.

Effects of d- and l-amphetamine on food intake: evidence for a dopaminergic substrate

The present experiment examined the effects of d- and l-amphetamine on the intake of sugar, sweetened rat chow and unsweetened rat chow in free feeding rats. Rats were injected IP with 4 doses of d- or l-amphetamine (0.0, 0.125, 0.50 and 2.00 mg/kg). Regardless of drug condition, animals were found to prefer sugar over sweetened or unsweetened chow. d-Amphetamine significantly increased food intake at 0.125 and 0.50 mg/kg doses but not at 2.00 mg/kg. l-Amphetamine had no significant effects at any dose. Further, d-amphetamine significantly increased sugar intake but not sweetened or unsweetened chow. Since d- and l-amphetamine are equipotent at releasing noradrenaline, while d-amphetamine is 2 to 5 times more potent at releasing dopamine, the results suggest that d-amphetamine-induced feeding is associated with activation of a dopaminergic substrate.

Odor detection performance of rats following d-amphetamine treatment: a signal detection analysis

The effects of d-amphetamine sulfate (0.2, 0.4, 0.8, and 1.6 mg/kg SC) on the odor detection performance of 16 adult male Long Evans rats was assessed using high precision olfactometry and a go/no-go operant signal detection task. The drug or saline was administered every 3rd day in a counterbalanced order, with the injections occurring 5 min before each 260-trial test session. Relative to saline, enhanced detection performance to the target stimulus (ethyl acetate), as measured by a non-parametric signal detection index (SI), was observed following administration of 0.2 mg/kg of the drug, whereas decreased detection performance was observed following administration of 1.6 mg/kg of the drug. Significant increases in the responsivity index (RI) occurred at the higher drug dosages for the lower odorant concentrations. In addition, small but statistically significant increases in the latency to respond in the presence of the odor (i.e., S+ response latency) were present at the higher drug dosages. Overall, these data suggest that (a) odor detection performance is enhanced by low doses of amphetamine, (b) odor detection performance is depressed by moderate doses of amphetamine, and (c) drug-related alterations in response criteria occur following the administration of moderate doses of amphetamine.